Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Oncternal Therapeutics

09/05/2024 22:01

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of $2.83​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-4.00.  The mean expectation of four analysts
for the quarter was for a loss of $2.88 per share. Wall Street
expected results to range from $-3.30 to $-2.46 per share.
    * Revenue rose 180.3% to $569.00 thousand from a year ago;
analysts expected $176.67 thousand. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of $2.83​.
    * The company reported a quarterly loss of $8.39 million.
    * Oncternal Therapeutics Inc shares had fallen by 4.9% this
quarter and lost 20.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 18.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $28.00 

This summary was machine generated from LSEG data May 9 at 09:01
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -2.88          -2.83          Beat
 Dec. 31 2023      -3.07          -3.11          Missed
 Sep. 30 2023      -2.90          -3.40          Missed
 Jun. 30 2023      -3.20          -3.00          Beat